Maplight Therapeutics, INC Form 4 insider transactions

MapLight Therapeutics Director Robert C. Malenka sold shares to cover tax liabilities related to restricted stock unit awards.

MapLight Therapeutics Director Robert C. Malenka sold 34,398 shares of common stock to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, disposed of 45,055 common shares at $17.98 to cover tax withholding obligations.

MapLight Therapeutics' Chief Discovery Officer, Anatol Kreitzer, disposed of 42,099 common shares to satisfy tax withholding obligations.

MapLight Therapeutics CEO Christopher A. Kroeger reported a disposition of shares to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, disposed of 22,050 shares of common stock to cover tax obligations related to restricted stock unit awards.

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, disposed of 44,616 common shares to cover tax withholding obligations.

MapLight Therapeutics' General Counsel, Kristopher Hanson, disposed of 26,007 shares of common stock to cover tax withholding obligations related to RSU settlement.

Novo Holdings A/S converted preferred shares and purchased additional common stock in MapLight Therapeutics' initial public offering, increasing its beneficial ownership.

Catalyst4, Inc. increased its indirect beneficial ownership in MapLight Therapeutics, Inc. to 19,697,464 voting common shares following an IPO-related conversion of preferred stock and a direct purchase.

MapLight Therapeutics' Chief Financial Officer, Vishwas Setia, was granted 43,367 restricted stock units and options to purchase 176,031 shares of common stock.

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, was granted 48,275 restricted stock units and options to purchase 196,035 shares of common stock.

MapLight Therapeutics Director Robert C. Malenka reported the future acquisition of restricted stock units and employee stock options, alongside the conversion of Series C Preferred Stock into common stock, all under a Rule 10b5-1 plan.

MapLight Therapeutics CEO Christopher A. Kroeger reported significant acquisitions of company stock and options, including 225,693 restricted stock units and 916,164 employee stock options.

MapLight Therapeutics, Inc. Director Timothy John Garnett was granted 6,294 restricted stock units and 25,604 employee stock options on October 27, 2025.

MapLight Therapeutics Director Maria C. Walker received restricted stock units and stock options as part of her compensation.

MapLight Therapeutics' General Counsel, Kristopher Hanson, received awards of 27,098 restricted stock units and options for 110,046 shares of common stock.

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, was granted 30,565 restricted stock units and 124,022 employee stock options.

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, received 32,539 restricted stock units and options for 132,023 shares.

MapLight Therapeutics' Chief Discovery Officer, Anatol Kreitzer, received 35,953 restricted stock units and 146,052 employee stock options.